小児用医薬品の世界市場の動向と予測：第 2 版

Abstract

Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future.

Addressing the needs of the pediatric population is a challenge of managing human responses within a changing tapestry of anatomic, physiologic, and psychosocial variations. With patients ranging in age from 24 weeks gestation to 18 years and older, optimal health care and patient outcomes can be achieved only through an awareness of the developmental phenomena affecting the responses of infants and children to health problems.

Important regulatory factors are also at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. The support of the U.S FDA in mandating pediatric labeling has played an important role in providing the motivation to manufacturers to work with clinicians and researchers in academic settings to study both new and established drugs in children. The result has been and will continue to be an increase in both the quantity and quality of pediatric drugs worldwide.

This completely updated edition of Kalorama's 2003 study on prescription pediatric drugs focuses on the following treatment segments:

• Allergy and Respiratory Drugs
• Anti-Infectives
• Cancer Therapies
• Cardiovascular Drugs
• Central Nervous System Drugs
• Gastrointestinal Drugs
• Hormone Drugs
• Other Drugs

The 500-page report includes global statistical information for conditions and diseases affecting pediatric populations, including detailed discussions and over 180 exhibits. Each segment provides an

• overview,
• descriptions of products on the market,
• market estimates and forecasts (U.S. and non-U.S.), and
• competitive analysis of leading providers including market share

In addition, the report includes extensive tables of products in R&D and approved prescription drugs for which additional pediatric information may produce health benefits in the pediatric population. There are also in-depth discussions of current issues and trends affecting the industry and what trends may arise in the future.

The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 100 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information-specifically revenue and market share data-presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertain to the world market at the manufacturers' level. The base year for data was 2004. Historical data are provided for 2002 and 2003 with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009, and 2002-2009 periods for each industry segment covered.

Table of Contents

Chapter One Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting the World Prescription Pediatric Market
• Leading Competitors

Chapter Two Introduction

• The Evolution of Child Healthcare
• History and Growth of the Pediatric Drug Market
  • Absorption
  • Distribution
  • Biotransformation
  • Excretion
• Demographics
• Treatment Guidelines for Pediatric Populations

Chapter Three Prescription Allergy and Respiratory Drugs

• Overview
• Description of Conditions and Diseases
  • Seasonal Conditions
  • Long Term Conditions
  • Prevalence and Incidence
• Description of Products
  • Antihistamines and Combinations
  • Antiasthmatic Agents
  • Bronchodilators
  • Corticosteroids
  • Decongestants and Combinations
  • Expectorants, Antitussives, and Combinations
  • Lung Surfactants
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
  • Competitive Analysis

Chapter Four Prescription Pediatric Anti-Infectives

• Overview
• Description of Conditions and Diseases
  • Respiratory Viral and Bacterial Conditions and Diseases
  • Upper Respiratory Tract Infections
  • Blood and Immune-Related Bacterial and Viral Infections
  • Childhood Diseases
  • Urinary Tract Infections (UTI)
  • Parasitic Infections
  • Miscellaneous Bacterial and Viral Infections
  • Prevalence and Incidence
• Description of Products
  • Antibiotics
  • Antifungals
  • Anti-Parasitics
  • Antivirals
  • Miscellaneous Anti-Infectives
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Five Prescription Pediatric Cancer Therapies

• Overview
• Description of Diseases
  • Leukemia
  • Lymphomas
  • Brain Tumors
  • Neuroblastoma
  • Osteogenic Sarcoma
  • Ewings Sarcoma
  • Wilms Tumor
  • Rhabdomyosarcoma
  • Retinoblastoma
• Incidence
• Description of Products
  • Alkylating Agents
  • Antimetabolites
  • Antineoplastic Antibiotics
  • Mitotic Inhibitors
  • Miscellaneous Cancer Therapies
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Six Prescription Pediatric Cardiovascular Drugs

• Overview
• Description of Conditions and Diseases
  • Congenital Heart Disease (CHD)
  • Congestive Heart Failure (CHF)
  • Hypertension
  • Hyperlipidemia/Hypercholesterolemia
  • Cardiomyopathy
• Prevalence and Incidence
  • Congenital Heart Disease
  • Congestive Heart Failure
  • Hypertension
  • Hyperlipidemia/Hypercholesterolemia
  • Cardiomyopathy
• Description of Products
  • Anticoagulants
  • Antidysrhythmics
  • Antihypertensives
  • Cardiac Glycosides
  • Miscellaneous Cardiovascular Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
  • Competitive Analysis

Chapter Seven Prescription Pediatric Central Nervous System Drugs

• Overview
• Description of Conditions and Diseases
  • Epilepsy
  • Attention Deficit Hyperactivity Disorder
  • Childhood Depression
  • Mental Disorders
  • Pain
  • Anesthesia
  • Enuresis
  • Juvenile Rheumatoid Arthritis
• Prevalence and Incidence
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Childhood and Adolescent Depression
  • Enuresis
  • Epilepsy
  • Juvenile Rheumatoid Arthritis
  • Other Mental Disorders
• Description of Products
  • Analgesics and Non-Steroidal Anti-inflammatory Drugs
  • Anesthetics
  • Antidepressants
  • Antipsychotics
  • Antiseizure Agents
  • Central Nervous Stimulants
  • Sedatives, Hypnotics, and Anxiolytics
• Miscellaneous Central Nervous System Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Eight Prescription Pediatric Gastrointestinal Drugs

Overview Description of Conditions and Diseases Chronic Conditions Acute Conditions Prevalence and Incidence Gastroesophageal Reflux (GER) Inflammatory Bowel Disease Peptic Ulcer Disease Irritable Bowel Syndrome Description of Products Antidiarrheals Antiemetics/Emetics Histamine H2 Antagonists Miscellaneous Gastrointestinal Drugs (Including PPIs) Market Analysis Market by Product Type Market by Geographical Region Competitive Analysis

Chapter Nine Prescription Pediatric Hormone Drugs

• Overview
• Description of Conditions and Diseases
  • Hypopituitarism
  • Precocious Puberty
  • Diabetes Insipidus
  • Hypothyroidism
  • Hyperthyroidism
  • Lymphocytic Thyroiditis
  • Diabetes Mellitus
• Prevalence and Incidence
  • Diabetes Insipidus
  • Diabetes Mellitis
  • Hyperthyroidism
  • Hypopitutitarism
  • Hypothyroidism
  • Lymphocytic Thyroiditis
  • Precocious Puberty
• Description of Products
  • Antidiabetic Agents
  • Antidiuretic Hormones
  • Growth Hormone Drugs
  • Steroids/Corticosteroids
  • Thyroid Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Ten Other Prescription Pediatric Drugs

• Overview
• Description of Conditions and Diseases
  • Dental
  • Dermatological
  • Ophthalmic
• Prevalence and Incidence
  • Acne
  • Dental Caries
  • Glaucoma
• Description of Products
  • Dental Products
  • Dermatologic Drugs
  • Ophthalmic Drugs
  • Miscellaneous Drugs
• Market Analysis
  • Market by Product Type
  • Market by Geographical Region
• Competitive Analysis

Chapter Eleven Pediatric Research and Development

• Overview

Chapter Twelve Issues and Trends Affecting the Pediatric Drug Market

• Drug Research and Children
• Pediatric Exclusivity Provision
• The Pediatric Rule
• Clinical Trials for Pediatric Populations
• Geographical Issues and Trends
• Compliance Issues
• Formulation Formula
• Off-Label Use of Adult Drugs on Children
• Labeling for Pediatric Indications
• Marketing Strategies for Manufacturers
  • Patent Life Extensions
• FDA Initiatives
  • Global Initiatives
• Pharmaceutical Company Challenges
  • Internal Challenges
  • Solutions
  • External Challenges
• Advertising

Chapter Thirteen Total Market Size and Forecast

• Overview
• Total market Size and Forecast
• Markets by Segments
• Competitor Analysis
• Market Analysis

Chapter Fourteen Corporate Profiles

Introduction Leading Corporate Profiles Abbott Laboratories Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Eli Lilly & Company Genentech, Inc. GlaxoSmithKline Johnson & Johnson Group MedImmune, Inc. Merck & Company, Inc. Novartis Pharmaceuticals Corporation Novo Nordisk Pharmaceuticals, Inc. Pfizer, Inc. Roche Sanofi-Aventis Schering-Plough Corporation Wyeth Other and Emerging Companies at a Glance Alcon Pharmaceuticals Alkermes, Inc. Allergan Antex Biologics Ascent Pediatrics AstraZeneca plc Celltech Group plc Chiron Corporation Daiichi Pharmaceutical Discovery Laboratories, Inc. Elan Corporation plc Genzyme Corporation Targacept (Layton BioSciences) Mallinckrodt Pharmaceuticals Milkhaus Laboratory, Inc. Muro Pharmaceutical, Inc. Nastech Pharmaceutical Company, Inc. Orphan Medical, Inc. Pharmacyclics, Inc. Sepracor, Inc. Shire Pharmaceuticals Group PLC Triangle Pharmaceuticals, Inc. Valeant Pharmaceuticals Vertex Pharmaceuticals, Inc. Appendix Company Directory

list of exhibits

Chapter One

• Table 1-1 The World Market for Prescription Pediatric Drugs, 2002-2009
• Figure 1-1 The World Market for Prescription Pediatric Drugs, 2002-2009

Chapter Two

• Table 2-1 Total World and Regional Pediatric Populations by Age Group 2002-2009
• Figure 2-1 World Pediatric Population by Geographic Region 2002, 2004, 2009
• Table 2-2 World Pediatric Population by More and Less Developed Countries (in millions) 2002, 2004, 2009
• Figure 2-2 World Pediatric Population by More and Less Developed Countries 2002, 2004, 2009
• Table 2-3 World Population Distribution by Age Group 2002-2050

Chapter Three

• Table 3-1 World Prevalence, Incidence and Mortality of Selected Pediatric Allergy and Respiratory Conditions
• Figure 3-1 World Prevalence of Selected Pediatric Respiratory Conditions in Comparison to the Total Pediatric Population
• Table 3-2 Selected Prescription Antihistamines and Combinations for Pediatric Administration
• Table 3-3 Selected Prescription Antiasthmatics for Pediatric Administration
• Table 3-4 Selected Prescription Bronchodilators for Pediatric Administration
• Table 3-5 Selected Prescription Corticosteroids for Pediatric Administration
• Table 3-6 Selected Prescription Decongestants and Combinations for Pediatric Administration
• Table 3-7 Selected Prescription Expectorants for Pediatric Administration
• Table 3-8 Selected Prescription Lung Surfactants for Pediatric Administration
• Table 3-9 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, 2002-2009
• Figure 3-2 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, 2002-2009
• Table 3-10 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Product Type (Antihistamines/Combinations, Antiasthmatics, Bronchdilators, Corticosteroids, Decongestants/Combinations, Expectorants/Antitussives/Combinations, Lung Surfectants) 2002-2009
• Figure 3-3 The World Market for Prescription Pediatric Allergy and Respiratory Drugs, by Product Type, 2002-2009
• Figure 3-4 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Product Type and Percent Distribution, 2002-2009
• Figure 3-5 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Percent and Product Type, 2004
• Table 3-11 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Geographic Region (U.S. vs. Non-U.S) 2002, 2004, and 2009
• Figure 3-6 The World Market for Prescription Pediatric Allergy and Respiratory Drugs by Geographic Region, 2002, 2004, and 2009
• Table 3-12 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Allergy and Respiratory Drugs, 2004
• Figure 3-7 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Allergy and Respiratory Drugs, 2004

Chapter Four

• Table 4-1 Global Prevalence, Incidence and Mortality of Selected Viral and Bacterial Infections
• Figure 4-1 World Incidence of Selected Pediatric Viral and Bacterial Infections in Comparison to Pediatric Population
• Figure 4-2 World Prevalence of Selected Pediatric Viral Infections in Comparison to Total Pediatric Population
• Table 4-2 Selected Prescription Antibiotics for Pediatric Administration
• Table 4-3 Selected Prescription Antifungals for Pediatric Administration
• Table 4-4 Selected Prescription Antiparasitics for Pediatric Administration
• Table 4-5 Selected Prescription Anti-virals for Pediatric Administration
• Table 4-5 Selected Prescription Anti-virals for Pediatric Administration
• Table 4-7 Selected Prescription Miscellaneous Anti-infectives for Pediatric Administration
• Table 4-9 The World Market for Prescription Pediatric Drugs: Anti-infectives, 2002-2009
• Figure 4-3 The World Market for Prescription Pediatric Drugs: Anti-infectives, 2002-2009
• Table 4-8 The World Market for Prescription Pediatric Anti-Infectives by Product Type, 2002-2009
• Figure 4-4 The World Market for Prescription Pediatric Anti-Infectives by Product Type 2002-2009
• Table 4-9 The World Market for Prescription Pediatric Anti-infectives by Geographic Region, 2002, 2004, and 2009
• Figure 4-5 The World Market for Prescription Pediatric Anti-infectives by Geographic Region, 2002, 2004, and 2009
• Table 4-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Anti-Infectives, 2004
• Figure 4-6 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Anti-Infectives, 2004

Chapter Five

• Table 5-1 World Incidence of Selected Pediatric Cancers
• Figure 5-1 World Incidence of Selected Pediatric Cancers as a Comparison to All Pediatric Cancers
• Table 5-2 Selected Prescription Alkylating Agents for Pediatric Administration
• Table 5-3 Selected Prescription Antimetabolites for Pediatric Administration
• Table 5-4 Selected Prescription Antineoplastic Antibiotics for Pediatric Administration
• Table 5-5 Selected Prescription Mitotic Inhibitors for Pediatric Administration
• Table 5-6 Selected Prescription Miscellaneous Cancer Therapies for Pediatric Administration
• Table 5-7 The World Market for Prescription Pediatric Cancer Therapies, 2002-2009
• Figure 5-2 The World Market for Prescription Pediatric Cancer Therapies, 2002-2009
• Table 5-8 The World Market for Prescription Pediatric Cancer Therapies, by Product Type 2002-2009
• Figure 5-3 The World Market for Prescription Pediatric Cancer Therapies by Product Type, 2002-2009
• Figure 5-5 The World Market for Prescription Pediatric Cancer Therapies, Distribution of Revenues by Product Type 2004
• Table 5-9 The World Market for Prescription Pediatric Cancer Therapies, by Geographic Region, 2002, 2004, and 2009
• Figure 5-6 The World Market for Prescription Pediatric Cancer Therapies by Geographic Region, 2002, 2004, and 2009
• Table 5-10 Leading Suppliers Shares of the World Market for Prescription PediatricCancer Therapies, 2004
• Figure 5-7 Leading Suppliers Shares of the World Market for Prescription Pediatric Cancer Therapies, 2004

Chapter Six

• Table 6-1 World Prevalence, Incidence and Mortality of Cardiovascular Conditions in Pediatric Population
• Figure 6-1 World Prevalence of Pediatric Cardiovascular Conditions in Comparison to Pediatric Populations
• Table 6-2 Selected Prescription Anticoagluants for Pediatric Administration
• Table 6-3 Selected Prescription Antidysrhythmics for Pediatric Administration
• Table 6-4 Selected Prescription Antihypertensives for Pediatric Administration
• Table 6-5 Selected Prescription Cardiac Glycosides for Pediatric Administration
• Table 6-6 Selected Prescription Miscellaneous Cardiovascular Drugs for Pediatric Administration
• Table 6-7 The World Market for Prescription Pediatric Drugs: Cardiovascular Drugs, 2002-2009
• Figure 6-2 The World Market for Prescription Pediatric Drugs: Cardiovascular Drugs, 2002-2009
• Table 6-8 The World Market for Prescription Pediatric Cardiovascular Drugs by Product Type (Anticoagulants, Antidysrhythmics, Antihypertensives, Cardiac Glycosides, Misc) 2002-2009
• Figure 6-3 The World Market for Prescription Pediatric Cardiovascular Drugs by Product Type, 2002-2009
• Figure 6-4 The World Market for Prescription Pediatric Cardiovascular Drugs, Revenue Distribution by Product Type, 2004
• Table 6-9 The World Market for Prescription Pediatric Cardiovascular Drugs by Geographic Region, 2002, 2004, and 2009
• Figure 6-5 The World Market for Prescription Pediatric Cardiovascular Drugs by Geographic Region, 2002, 2004, and 2009
• Table 6-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Cardiovascular Drugs, 2004
• Figure 6-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Cardiovascular Drugs, 2004

Chapter Seven

• Table 7-1 World Prevalence of Selected Pediatric Central Nervous System Conditions
• Figure 7-1 World Prevalence of Selected Pediatric Central Nervous System Conditions in Comparison to Pediatric Population
• Table 7-2 Selected Prescription Analgesic and Non-steroidal Anti-inflammatory Drugs for Pediatric Administration
• Table 7-3 Selected Prescription Anesthetics for Pediatric Administration
• Table 7-4 Selected Prescription Antidepressants for Pediatric Administration
• Table 7-5 Selected Prescription Antipsychotic Drugs for Pediatric Administration
• Table 7-6 Selected Prescription Antiseizure Agents for Pediatric Administration
• Table 7-7 Selected Prescription Central Nervous Stimulants for Pediatric Administration
• Table 7-8 Selected Prescription Sedatives, Hypnotics, and Anxiolytics for Pediatric Administration
• Table 7-9 Selected Prescription Miscellaneous Central Nervous System Agents for Pediatric Administration
• Table 7-10 The World Market for Prescription Pediatric Central Nervous System Drugs, 2002-2009
• Figure 7-2 The World Market for Prescription Pediatric Central Nervous System Drugs, 2002-2009
• Table 7-11 The World Market for Prescription Pediatric Central Nervous System Drugs by Product Type (Analgesics/NSAIDs, Anesthetics, Anti-depressants/Antipsychotics, Antiseizure Agents, CNS Stimulants, Sedatives/Hypnotics/Anxiolytics, and Miscellaneous ), 2002-2009
• Figure 7-3 The World Market for Prescription Pediatric Central Nervous System Drugs by Product Type, 2002-2009
• Figure 7-4 The World Market for Prescription Pediatric Central Nervous System Drugs, Revenue Distribution by Product Type, 2004
• Table 7-12 The World Market for Prescription Pediatric Central Nervous System Drugs by Geographic Region 2002, 2004, and 2009
• Figure 7-5 The World Market for Prescription Pediatric Central Nervous System Drugs by Geographic Region, 2002, 2004, and 2009
• Table 7-13 Leading Suppliers Shares of the World Market for Prescription Pediatric Central Nervous System Drugs, 2004
• Figure 7-6 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Central Nervous System Drugs, 2004

Chapter Eight

• Table 8-1 Global Prevalence, Incidence, and Mortality of Gastrointestinal Conditions in Pediatric Populations
• Figure 8-1 World Incidence of Pediatric Gastrointestinal Conditions in Comparison to Pediatric Population
• Figure 8-2 World Prevalence of Pediatric Gastrointestinal Conditions Compared to Pediatric Populations
• Table 8-2 Selected Prescription Antidiarrheals for Pediatric Administration
• Table 8-3 Selected Prescription Antiemetics/Emetics Drugs for Pediatric Administration
• Table 8-4 Selected Prescription Histamine H2 Antagonists for Pediatric Administration
• Table 8-5 Selected Prescription Miscellaneous Gastrointestinal Drugs for Pediatric Administration
• Table 8-6 The World Market for Prescription Pediatric Gastrointestinal Drugs 2002-2009
• Figure 8-3 The World Market for Prescription Pediatric Gastrointestinal Drugs 2002-2009
• Table 8-7 The World Market for Prescription Pediatric Gastrointestinal Drugs by Product Type (Antidiarrheals, Antiemetics/Emetics, H2 Antagonists, Misc Drugs incl PPIs) 2002-2009
• Figure 8-4 The World Market for Prescription Pediatric Gastrointestinal Drugs by Product Type, 2002-2009
• Figure 8-5 The World Market for Prescription Pediatric Gastrointestinal Drugs, Revenue Distribution by Product Type, 2004
• Table 8-7 The World Market for Prescription Pediatric Gastrointestinal Drugs by Geographic Region, 2002, 2004, and 2009
• Figure 8-6 The World Market for Prescription Pediatric Gastrointestinal Drugs by Geographic Region, 2002, 2004, and 2009
• Table 8-8 Leading Suppliers Shares of the World Market for Prescription Pediatric Gastrointestinal Drugs, 2004
• Figure 8-11 Leading Suppliers Shares of the World Market for Prescription Pediatric Gastrointestinal Drugs, 2004

Chapter Nine

• Table 9-1 World Incidence and Prevalence of Selected Pediatric Hormone Conditions
• Figure 9-1 World Incidence of Selected Pediatric Hormone Conditions in Comparison to Pediatric Population
• Figure 9-2 World Prevalence of Selected Pediatric Hormone Conditions in Comparison to Pediatric Population
• Table 9-2 Selected Prescription Antidiabetic Agents for Pediatric Administration
• Table 9-3 Selected Prescription Antidiuretic Hormones for Pediatric Administration
• Table 9-4 Selected Prescription Growth Hormone Drugs for Pediatric Administration
• Table 9-5 Selected Prescription Steroids/Corticosteroids for Pediatric Administration
• Table 9-6 Selected Prescription Thyroid Drugs for Pediatric Administration
• Table 9-7 The World Market for Prescription Pediatric Hormone Drugs, 2002-2009
• Figure 9-2 The World Market for Prescription Pediatric Hormone Drugs, 2002-2009
• Table 9-8 The World Market for Prescription Pediatric Hormone Drugs by Product Type, 2002-2009
• Figure 9-3 The World Market for Prescription Pediatric Hormone Drugs by Product Type, 2002-2009
• Figure 9-4 The World Market for Prescription Pediatric Hormone Drugs, Revenue Distribution by Product Type, 2004
• Table 9-9 The World Market for Prescription Pediatric Hormone Drugs by Geographic Region, 2002, 2004, and 2009
• Figure 9-7 The World Market for Prescription Pediatric Drugs: Hormone Drugs, by Geographic Region, 2002, 2004, and 2009
• Table 9-10 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Hormone Drugs, 2004
• Figure 9-11 Leading Suppliers Shares of the World Market for Prescription Pediatric Drugs: Hormone Drugs, 2004

Chapter Ten

• Table 10-1 World Incidence of Other Pediatric Conditions
• Figure 10-2 World Incidence/Prevalence of Other Pediatric Conditions in Comparison to Pediatric Populations
• Table 10-2 Selected Prescription Dental Products for Pediatric Administration
• Table 10-3 Selected Prescription Dermatologic Drugs for Pediatric Administration
• Table 10-4 Selected Prescription Ophthalmic Drugs for Pediatric Administration
• Table 10-5 Selected Prescription Miscellaneous Drugs for Pediatric Administration
• Table 10-6 The World Market for Miscellaneous Pediatric Prescription Drugs 2002-2009
• Figure 10-2 The World Market for Miscellaneous Pediatric Prescription Drugs, 2002-2009
• Table 10-7 The World Market for Miscellaneous Pediatric Prescription Drugs by Product Type, 2002-2009
• Figure 10-3 The World Market for Miscellaneous Pediatric Prescription Drugs by Product Type, 2002-2009
• Figure 10-4 The World Market for Miscellaneous Pediatric Prescription Drugs, Revenue Distribution by Product Type 2004
• Table 10-8 The World Market for Miscellaneous Pediatric Prescription Drugs, by Geographic Region, 2002, 2004, and 2009
• Figure 10-5 The World Market for Miscellaneous Pediatric Prescription Drugs, by Geographic Region, 2002, 2004, and 2009

Chapter Eleven

• Table 11-1 Products Recently Approved or in Various Stages of Development for Pediatrics
• Table 11-2 Approved Prescription Drugs for which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population
• Table 11-3 Approved Prescription Biologics for which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population

Chapter Twelve

• Table 12-1 Label Changes for Pediatric Drugs
• Table 12-2 FDA Approved Drugs with Pediatric Exclusivity and Patent Expiration Date
• Table 12-3 Requests Issued and Received for Pediatric Exclusivity by FDA Review Division as of September, 2005

Chapter Thirteen

• Table 13-1 The World Market for Prescription Pediatric Drugs, 2002-2009
• Figure 13-1 The World Market for Prescription Pediatric Drugs, 2002-2009
• Table 13-2 The World Market for Prescription Pediatric Drugs by Therapeutic Area, 2002-2009
• Figure 13-2 The World Market for Prescription Pediatric Drugs by Therapeutic Area, 2002-2009
• Figure 13-4 The World Market for Prescription Pediatric Drugs, Revenue Distribution by Therapeutic Area, 2004
• Table 13-5 Leading Suppliers Segments of Participation in the World Market for Prescription Pediatric Drugs, 2004

Chapter Fourteen

Appendix